Since the online publication of this article, the authors have noticed the following errors: 1) The following authors were missing the middle initial in their name; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola

Since the online publication of this article, the authors have noticed the following errors: 1) The following authors were missing the middle initial in their name; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola. The Mivebresib (ABBV-075) author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article. Paolo Antonio Ascierto,1 Bernard A Fox,2 Walter J Urba,2 Ana Carrizosa Anderson,3 Michael B Atkins,4 Ernest C Borden,5 Julie R Brahmer,6 Lisa H Butterfield,7 Alessandra Cesano,8 Daniel S Chen,9 Tanja D de Gruijl,10 Robert O Dillman,11 Charles G Drake,12 Leisha A Emens,13 Thomas F Gajewski,14 James L Gulley,15 F Stephen Hodi MKK6 Jr,16 Patrick Hwu,17 David Kaufman,18 Howard L Kaufman,19 Michael T Lotze,20 Douglas G McNeel,21 Kim A Margolin,22 Francesco M Marincola,23 Michael J Mastrangelo,24 Marcela V Maus,25 David R Parkinson,26 Pedro J Romero,27 Paul M Sondel,28 Stefani Spranger,29 Mario Sznol,30 George J Weiner,31 Jon M Wigginton,32 Jeffrey S Weber33 2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affiliations 8, 32, 34 have been removed. The updated affiliation list is usually shown below and has been updated in the article. 1Istituto Nazionale Tumori IRCCS Fondazione ‘G. Pascale’, Naples, Italy 2Earle A. Chiles Research Institute, Providence Malignancy Institute, Portland, Oregon, USA 3Harvard Medical School, Boston, Massachusetts, USA 4Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA 5University of Wisconsin Clinical Malignancy Center, Madison, Wisconsin, USA 6Johns Hopkins University or college School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA 7Research, Parker Institute for Malignancy Immunotherapy, San Francisco, California, USA 8ESSA Pharma Inc, Redwood City, California, USA 9IGM Biosciences Inc, Mountain View, California, USA 10Medical Oncology – Amsterdam University Medical Centers, Vrije Universiteit-Cancer Center Amsterdam, Amsterdam, The Netherlands 11AIVITA Biomedical, Inc, Irvine, California, USA 12Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA 13UPMC Hillman Malignancy Center, Pittsburgh, Pennsylvania, USA 14Pathology and Medicine, Immunology and Cancer Program, University or college of Chicago, Chicago, Illinois, USA 15National Malignancy Institute, Bethesda, Maryland, USA 16Dana Farber Malignancy Institute, Boston, Massachusetts, USA 17University of Texas MD Anderson Malignancy Center, Houston, Texas, USA 18Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA 19Immuneering Corp New York, New York, New York, USA 20University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA 21Carbone Cancer Center, University or college of Wisconsin-Madison, Madison, Wisconsin, USA 22Medical Oncology, City of Hope National Medical Center, Duarte, California, USA 23Refuge Biotechnologies, Menlo Park, California, USA 24Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA 25Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA 26ESSA Pharma Inc, Palo Alto, California, USA 27Oncology, University or college of Lausanne, Lausanne, VD, Switzerland 28Pediatrics, University or college of Wisconsin Madison, Madison, Wisconsin, USA 29Massachusetts Institute of Mivebresib (ABBV-075) Technology Koch Institute for Integrative Malignancy Research, Cambridge, Massachusetts, USA 30Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA 31Holden Comprehensive Cancer Center, The School of Iowa, Iowa Town, Iowa, USA 32MacroGenics Inc, Rockville, Maryland, USA isaac and 33Laura Perlmutter In depth Cancers Middle, NYU Langone INFIRMARY, New York, NY, USA 3) In the primary text, The phrase The hypoxia and profound inflammatory response from the pneumonitis observed using the severe acute respiratory virus coronavirus-2 SARS-COV-2 virus now reads The hypoxia and profound inflammatory response from the pneumonitis observed using the SARS-CoV-2 virus The sentence One possibility is to encourage the usage of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma) now reads One possibility is to encourage the usage of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (ActemraTM, Roche-Genentech), sarilumab (KevzaraTM, Regeneron) and siltuximab (SylvantTM, EUSA Pharma) The sentence including tocilizumab and sarilumab for use on the compassionate basis to critically ill hospitalized COVID-19-infected patients in this extraordinary situation now reads including tocilizumab and sarilumab for use on the compassionate basis to critically ill hospitalized SARS-CoV-2-infected patients in this extraordinary situation 4) To acknowledge medical composing support, the acknowledgment section continues to be updated to learn: The authors thank the clinicians working tirelessly in the frontlines from the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for project management and assistance. Additionally, the authors wish to say thanks to the society for assisting the manuscript development. 5) In the competing interests section: Bristol-Myers Squibb was spelt incorrectly while Bristol-Myer Squibb and Bristol-Myers-Squibb The initials for Mivebresib (ABBV-075) authors BF, JB, ACA, DC, TdG. HK, ML, FM, KM now read BAF, JRB, AC, DSC, TDG, HLK, MTL, FMM, KAM. A Fox,2 Walter J Urba,2 Ana Carrizosa Anderson,3 Michael B Atkins,4 Ernest C Borden,5 Julie R Brahmer,6 Lisa H Butterfield,7 Alessandra Cesano,8 Daniel S Chen,9 Tanja D de Gruijl,10 Robert O Dillman,11 Charles G Drake,12 Leisha A Emens,13 Thomas F Gajewski,14 Wayne L Gulley,15 F Stephen Hodi Jr,16 Patrick Hwu,17 David Kaufman,18 Howard L Kaufman,19 Michael T Lotze,20 Douglas G McNeel,21 Kim A Margolin,22 Francesco M Marincola,23 Michael J Mastrangelo,24 Marcela V Maus,25 David R Parkinson,26 Pedro J Romero,27 Paul M Sondel,28 Stefani Spranger,29 Mario Sznol,30 George J Weiner,31 Jon M Wigginton,32 Jeffrey S Weber33 2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affiliations 8, 32, 34 have been removed. The updated affiliation list is definitely demonstrated below and has been updated in the article. 1Istituto Nazionale Tumori IRCCS Fondazione ‘G. Pascale’, Naples, Italy 2Earle A. Chiles Study Institute, Providence Malignancy Institute, Portland, Oregon, USA 3Harvard Medical School, Boston, Massachusetts, USA 4Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA 5University of Wisconsin Clinical Malignancy Center, Madison, Wisconsin, USA 6Johns Hopkins University or college School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA 7Research, Parker Institute for Malignancy Immunotherapy, San Francisco, California, USA 8ESSA Pharma Inc, Redwood City, California, USA 9IGM Biosciences Inc, Mountain Watch, California, USA 10Medical Oncology – Amsterdam School Medical Centers, Vrije Universiteit-Cancer Middle Amsterdam, Amsterdam, HOLLAND 11AIVITA Biomedical, Inc, Irvine, California, USA 12Herbert Irving In depth Cancer Middle, Columbia University INFIRMARY, New York, NY, USA 13UPMC Hillman Cancers Center, Pittsburgh, Pa, USA Medicine and 14Pathology, Immunology and Cancers Program, School of Chicago, Chicago, Illinois, USA 15National Cancers Institute, Bethesda, Maryland, USA 16Dana Farber Cancers Institute, Boston, Massachusetts, USA 17University of Tx MD Anderson Cancers Center, Houston, Tx, USA 18Bsick & Melinda Gates Medical Analysis Institute, Cambridge, Massachusetts, USA 19Immuneering Corp NY, New York, NY, USA 20University of Pittsburgh College of Medication, Pittsburgh, Pa, USA 21Carbone Cancers Center, School of Wisconsin-Madison, Madison, Wisconsin, USA 22Medical Oncology, Town of Hope Country wide INFIRMARY, Duarte, California, USA 23Refuge Biotechnologies, Menlo Recreation area, California, USA 24Thomas Jefferson Medical University, Philadelphia, Pa, USA 25Massachusetts General Medical center Cancer Middle, Harvard Medical College, Massachusetts General Hospital, Boston, Massachusetts, USA 26ESSA Pharma Inc, Palo Alto, California, USA 27Oncology, University or college of Lausanne, Lausanne, VD, Switzerland 28Pediatrics, University or college of Wisconsin Madison, Madison, Wisconsin, USA 29Massachusetts Institute of Technology Koch Institute for Integrative Malignancy Study, Cambridge, Massachusetts, USA 30Yale Malignancy Center, Yale School of Medicine, New Haven, Connecticut, USA 31Holden Comprehensive Cancer Center, The University or college of Iowa, Iowa City, Iowa, USA 32MacroGenics Inc, Rockville, Maryland, USA 33Laura and Isaac Perlmutter Comprehensive Tumor Center, NYU Langone Medical Center, New York, New York, USA 3) In the main text, The phrase The hypoxia and serious inflammatory response associated with the pneumonitis observed with the severe acute respiratory disease coronavirus-2 SARS-COV-2 disease today reads The hypoxia and deep inflammatory response from the pneumonitis noticed using the SARS-CoV-2 trojan The word One possibility is normally to encourage the usage of IL-6 or IL-6-receptor (IL-6R) preventing antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma) today reads One likelihood is to motivate the usage of IL-6 or IL-6-receptor (IL-6R) obstructing antibodies like tocilizumab (ActemraTM, Roche-Genentech), sarilumab (KevzaraTM, Regeneron) and siltuximab (SylvantTM, EUSA Pharma) The phrase including tocilizumab and sarilumab for make use of on the compassionate basis to critically sick hospitalized COVID-19-contaminated patients in this amazing situation right now reads including tocilizumab and sarilumab for make use of on the compassionate basis to critically sick hospitalized SARS-CoV-2-contaminated patients in this amazing situation 4) To acknowledge medical writing support, the acknowledgment section has been updated to read: The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for task administration and assistance. Additionally, the writers wish to say thanks to the culture for assisting the manuscript advancement. 5) In the contending passions section: Bristol-Myers Squibb was spelt improperly as Bristol-Myer Squibb and Bristol-Myers-Squibb The initials for writers BF, JB, ACA, DC, TdG. HK, ML, FM, Kilometres now examine BAF, JRB,.

Comments are closed.

Categories